A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease.
We carried out a double-blind rising dose study of a D-1 dopamine agonist, CY 208-243, in 6 parkinsonian patients. Deficits monitored by Columbia scores were significantly improved at single doses ranging from 5 to 40 mg, though efficacy was low. Used alone, CY 208-243 was not a satisfactory therapeutic agent, and toxicity data precluded further increases in dosage.
Tsui
J K
JK
Department of Medicine, University Hospital, University of British Columbia, Vancouver, Canada
Wolters
E C
EC
Peppard
R F
RF
Calne
D B
DB
D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010617:Phenanthridines / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos
D007211:Indoles; D010617:Phenanthridines; D010919:Placebos; C054531:CY 208-243